Skip to main content
PMC home page
Cytotechnology logoLink to Cytotechnology
. 2005 Jun;48(1-3):79–88. doi: 10.1007/s10616-005-3795-y

Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development

Philippe-Alexandre Gilbert 1, Lacrimioara Comanita 1, John Barrett 1, Andrew Peters 1, Marta Szabat 1, Grant McFadden 1, Gregory A Dekaban 1,✉
PMCID: PMC3449719  PMID: 19003034

Abstract

In light of the recent detection of BSE in North America and its endemic nature in other regions of the world, there is a real need to employ cell culture conditions that do not require any animal-derived material. Here we report the use of an ultra-low protein serum-free medium (VP-SFM, Invitrogen) for the amplification of poxviruses in primary chicken embryo fibroblasts (CEF). We compared the amplification of four different poxviruses (canarypox, modified Ankara Virus (MVA), vaccinia virus strain Copenhagen and myxoma strain Lausanne) in three different media: DMEM 10%, DMEM 2% and serum-free medium VP-SFM. VP-SFM is a serum-free, ultra-low protein medium containing no proteins or peptides of human or animal origin designed to support the replication of viruses and the production of recombinant proteins and monoclonal antibodies. Our results show that high titre poxvirus stocks can be prepared in VP-SFM equivalent to that prepared in serum containing medium.

Keywords: Chicken embryo fibroblasts (CEF), Canarypox virus (ALVAC), Modified Ankara Virus (MVA), Poxvirus, Serum-free medium, Vaccinia virus, VP-SFM

Full Text

The Full Text of this article is available as a PDF (385.2 KB).

References

  1. Chakrabarti S., Sisler J.R., Moss B. Compactsynthetic, vaccinia virus early/late promoter for protein expression. Biotechniques. 1997;23:1094–1097. doi: 10.2144/97236st07. [DOI] [PubMed] [Google Scholar]
  2. Earl P.L., Cooper N., Wyatt L.S., Moss B., Carroll M.W. Preparation of cell cultures and vaccinia virus stocks. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K., editors. Current Protocols in Molecular Biology. New York: Greene Pub. Associates and Wiley Interscience; 1998a. pp. 16.16.1–16.16.13. [Google Scholar]
  3. Earl P.L., Moss B., Wyatt L.S., Carroll M.W. Generation of recombinant vacinia viruses. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.G., Smith J.A., Struhl K., editors. Current Protocols in Molecular Biology. New York: Greene Pub. Associates and Wiley Interscience; 1998b. pp. 16.17.1–16.17.19. [Google Scholar]
  4. Fike R., Dadey B., Hassett R., Radominski R., Jayme D., Cady D. Advanced Granulation Technology (AGTTM). An alternate format for serum-freechemically-defined and protein-free cell culture media. Cytotechnology. 2001;36:33–39. doi: 10.1023/A:1014045104525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ford C.M., Arp J., Palker T.J., King E.E., Dekaban G.A. Characterization of the antibody response to three different versions of the HTLV-I envelope protein expressed by recombinant vaccinia viruses: induction of neutralizing antibody. Virology. 1992;191:448–453. doi: 10.1016/0042-6822(92)90208-7. [DOI] [PubMed] [Google Scholar]
  6. Griffiths J.B., Racher A.J. Cultural and physiological factors affecting expression of recombinant proteins. Cytotechnology. 1994;15:3–9. doi: 10.1007/BF00762374. [DOI] [PubMed] [Google Scholar]
  7. Hodgson J. Checking sources: the serum supply secret. Biotechnology. 1991;9:1320–1324. doi: 10.1038/nbt1291-1320. [DOI] [PubMed] [Google Scholar]
  8. Jayme D.W., Smith S.R. Media formulation options and manufacturing process controls to safeguard against introduction of animal origin contaminants in animal cell culture. Cytotechnology. 2000;33:27–36. doi: 10.1023/A:1008133717035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnston J.B., Barrett J.W., Chang W., Chung C.S., Zeng W., Masters J., Mann M., Wang F., Cao J., McFadden G. Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J. Virol. 2003;77:5877–5888. doi: 10.1128/JVI.77.10.5877-5888.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mayr A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine. Berl Munch Tierarztl Wochenschr. 1999;112(9):322–328. [PubMed] [Google Scholar]
  11. Merten O.W. Development of serum-free media for cell growth and production of viruses/viral vaccines – safety issues of animal products used in serum-free media. Dev. Biol. 2002;111:233–257. [PubMed] [Google Scholar]
  12. Opgenorth A., Graham K., Nation N., Strayer D., McFadden G. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J. Virol. 1992;66:4720–4731. doi: 10.1128/jvi.66.8.4720-4731.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Price P., Evege E., Nestler L., Grefrath P., Naumovic F., Fatunmbi F., Jayme D. A versatile serum-free medium for kidney epithelial cell growth and virus production. Focus. 2002;19(3):24–28. [Google Scholar]
  14. Radominski R., Hassett R., Dadey B., Fike R., Cady D. and Jayme D. 2001. Qualification of a novel cell culture medium format. BioPharm 14. [DOI] [PMC free article] [PubMed]
  15. Staib C., Sutter G. Vaccine protocols: live viral vectors: vaccinia virus. In: Robinson A., Hudson M.J., Cranage M.P., editors. Methods in Molecular Medecine. Totowa NJ: Humana Press; 2003. pp. 51–68. [DOI] [PubMed] [Google Scholar]
  16. Staib C., Drexler I., Sutter G. Vaccinia virus and poxvirology: methods and protocols. In: Isaacs S.N., editor. Methods in Molecular Biology. Towowa NJ: Humana Press; 2004. pp. 77–99. [Google Scholar]
  17. Staines D. and Price P. 2003. Perspectives in cell culture: managing serum requirements for cell culture. GIBCO Cell Culture.
  18. Zang M., Trautmann H., Gandor C., Messi F., Asselbergs F., Leist C., Fiechter A., Reiser J. Production of recombinant proteins in Chinese hamster ovary cells using a protein-free cell culture medium. Biotechnology. 1995;13:389–392. doi: 10.1038/nbt0495-389. [DOI] [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES